InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Appoints European Head of Sales
January 18, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has named Drahoslav Zdarek as its head of sales in Europe. According to the announcement, Zdarek will focus on developing distribution, sales and marketing of the company’s products; top on the list of assignments Zdarek will be […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Czech Republic Distribution Deal, Announces Rollout Plan for Additional European Territories
January 13, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has signed a distribution agreement with TechUnit s.r.o. (Limited). TechUnit is a privately owned company focused on medical product distribution, advertisement and promotion. The agreement outlines parameters for the distribution of XYPHY’s Covid-ID Lab in the Czech […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Strategic Appointments
January 10, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products, including for the detection of COVID-19. Roland Spleiss, a seasoned commercial […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces January 2022 Commencement of Epilepsy Clinical Trial
December 15, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today provided an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved in the planning and preparation for the pending pilot trial, the company announced that […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Completes Transformative Step in Commercial Strategy with 3a Acquisition
December 6, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has completed its acquisition of 3a-diagnostics GmbH (“3a”), first announced July 20, 2021. “The strategic acquisition of 3a is a transformative step in XPhyto’s commercial strategy,” said Peter Damouni, XPhyto director. […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Appoints New CFO
November 22, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has named a new chief financial officer: Joseph Meagher. A chartered professional accountant (“CPA, CA”) and a chartered director, Meagher most recently worked at Defence Therapeutics Corp, a publicly traded biotechnology company engineering next-generation vaccines and anti-body […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) Featured in Coverage of Investor Summit Group’s Q4 Virtual Event
November 10, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Shares Drug-Development Update
October 12, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released updated information regarding its drug formulation and development focus. The company is continuing its focus on advancing multiple generic and hybrid-generic programs for neurotherapeutics. Highlights of the update include that planning for XPhyto’s Rotigotine transdermal […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Extends Agreements with Partners
October 11, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has extended its investor relations consulting agreement with Knox Communications Inc. (“KCI”) and M. Davis & Associates Capital Inc. The agreements are designed to support XPhyto in its marketing and investor communications activities. The […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference
September 27, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug diagnostics, delivery and new active pharmaceutical ingredient investment opportunities, including: rapid, low-cost infectious disease test (EU approved rapid PCR test) and oral health screening tests; precision transdermal and oral dissolvable drug formulations; and standardization of emerging active pharmaceutical ingredients for neurological applications, including […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Proprietary COVID-19 PCR Test COVID-ID Lab Launch Deemed a Success
September 8, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that the market launch of its 25-minute COVID-19 PCR Test COVID-ID Lab has been a success. The company unveiled the project at test centers in Berlin, and XPhyto reports the successfully optimization of operational procedures and […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Registers First Oral Disease Biosensor for Commercialization
August 30, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has registered its first biosensor test in oral inflammation with German authorities. The company registered the easy, at-home, self-check test with the assistance of its partner and acquisition target, 3a-diagnostics GmbH (“3a”). The biosensor […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in “Forbes” Article Discussing Mescaline
August 13, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, was featured in an article titled “Is Mescaline a Key Component in the Future of Medicine? XPhyto Aims to Find Out.” The article notes that mescaline (3,4,5-trimethoxyphenethylamine), the magical alkaloid found in the peyote cactus and similar […]
InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates
July 28, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Definitive Agreement to Acquire 3a-Diagnostics
July 20, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, has signed a definitive agreement to acquire its exclusive diagnostics development partner 3a-diagnostics GmbH, Frickenhausen, Germany. Per the terms of the definitive agreement, XPhyto will acquire all outstanding shares of 3a for EUR 400,000, to be paid immediately, and EUR 3.5 million, to […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising
July 19, 2021
XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting […]
InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Covid-ID Lab Filling Existing Market Gap
July 13, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25. The company is likely to benefit from the country’s regulatory requirements and the government’s […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy
July 12, 2021
XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes XPhyto plans to capitalize on the rapid test market, projected to reach […]
XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track
June 30, 2021
XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significant milestone for the program Mescaline will form a critical component in XPhyto’s psychedelic medicine program […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Finalizes Supply Agreement with Two German Companies for COVID-19 PCR Test
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberries GmbH. The two companies run 10 COVID-19 test centers in Berlin. The supply agreement outlines […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advancing Rotigotine Development Program for Parkinson’s
June 22, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast
June 17, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, was featured in the Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director Hugh Rogers joined the latest episode to offer an operational update and discuss the company’s […]
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO of XPhyto Therapeutics Corp.
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of an exclusive The Bell2Bell Podcast interview with Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commences Sale of Rapid COVID-19 RT-PCR Test Kits in Germany Amid Potential Surge in Demand
June 15, 2021
XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25 Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the market The announcement comes as Germany reopens, meaning XPhyto is likely […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Looks to Focus Expertise on Psychedelic Drug Formulation as Manufacturing Programs Advance
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community. The audio press release discusses […]
XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies
VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) — via InvestorWire — XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update on Timely Progression of Psychedelic Medicine Program
June 8, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that its GMP mescaline synthesis program is on schedule with the completion of initial production batches. According to the update, the industrial-scale manufacture of pharmaceutical-grade psychedelic compounds, including mescaline and psilocybin, is an important part of XPhyto’s psychedelic medicine program and will provide a foundation […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Beginning 2021 Strong with New Drugs and Life Sciences Advancements
June 2, 2021
Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patients Wholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trial The company is planning the construction of a new lab and manufacturing space up to […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Potential Expansion of ‘Covid-ID Lab’
May 28, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently received the CE-IVD approval (European certification) of its 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”). The approval facilitated initial sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East and North America. The company […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Proprietary Covid-ID Lab to Launch in Germany
May 20, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that Marx Pharma GmbH, the company’s distribution, storage and logistics partner, is launching Covid-ID Lab, XPhyto’s 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system in Germany; the product will launch on May 25. The announcement noted that the […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Targets Potential Expansion of Rapid COVID-19 Test Kit Distribution with Delivery of 2,000 Units to Israel
May 18, 2021
XPhyto recently delivered 2,000 of its rapid Covid-ID Lab test kits to an established Israeli distributor for clinical evaluation by the Ministry of Health The delivery, which marks entry into the Middle East, follows the approval of the test kits in Europe In an earlier interview, CEO Hugh Rogers had noted that XPhyto was looking […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market
May 14, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Releases Business, Drug-Development Status
May 13, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry,released an update on its 2021 drug formulation programs, noting that the programs are advancing on schedule and expanding in scope. The company’s Rotigotine transdermal human pilot study was successfully completed in March and the program now advancing […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO Talks Business in Two Video Interviews
May 11, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. During his InvestorIntel interview with host Peter […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Launches ‘Covid-ID Lab’ POC Pilot Project in Germany
May 7, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its commencement of a pilot project with its rapid COVID-19 PCR test (“Covid-ID Lab”) in a point-of-care (“POC”) setting in Germany. Covid-ID Lab was recently approved in Europe and offers the accuracy of a PCR test in only 25 minutes. Validated work flows, including mobile […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured on Gamechangers LIVE
May 6, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. XPhyto Therapeutics’ CEO and Director, […]
InvestorBrandNetwork Announces Gamechangers LIVE Interview with XPhyto Therapeutics Corp. CEO and Director Hugh Rogers
LOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY) (OTC:XPHYF), recently appeared on Gamechangers LIVE, a podcast series putting a spotlight on individuals who are gamechangers in their fields and […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales
May 4, 2021
XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout Germany Germany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up sales Anticipating the increase in sales and distribution, XPhyto expanded […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Significant Market Opportunity
May 3, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, raised eyebrows when it announced that XPhyto Laboratories Inc., its Alberta subsidiary, added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/cHwJi). Mescaline has begun attracting legislative attention, much like was the case with cannabis, which gained widening legalization as state […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Pursues Market Access in Israel for ‘Covid-ID Lab’
April 28, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that it has delivered 2,000 of its rapid 25-minute PCR tests (“Covid-ID Lab”) to an established medical distributor in Israel for clinical evaluation of Covid-ID Lab for the purpose of commercial regulatory approval and potential product distribution. According to the update, the Israeli distributor markets […]